Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303836 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00303836: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00303836 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303836, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well giving vaccine therapy with or without interleukin-2 after chemotherapy and an autologous white blood cell infusion works in treating patients with metastatic melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy with interleukin-2, chemotherapy, and an autologous white blood cell infusion may be a more effective treatment for metastatic melanoma.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL gp100 antigen
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303836
The ClinicalTrials.gov registry entry for NCT00303836 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00303836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303836 about?
NCT00303836 is a clinical study titled "Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma". This randomized phase II trial is studying how well giving vaccine therapy with or without interleukin-2 after chemotherapy and an autologous white blood cell infusion works in treating patients with metastatic melanoma. Vaccines made from peptides may help the body build an effective immune respons...
What is the current status of trial NCT00303836?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2005-11.
What interventions are being tested in trial NCT00303836?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), gp100 antigen (BIOLOGICAL), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00303836?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.